Article
Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.
Virology journal - 2 Jun 2008
Israyelyan Anna, Chouljenko Vladimir N, Baghian Abolghasem, David Andrew T, Kearney Michael T, Kousoulas Konstantin G
Abstract excerpt
BACKGROUND: The NV1020 oncolytic herpes simplex virus type-1 has shown significant promise for the treatment of many different types of tumors in experimental animal models and human trials. Previously, we described the construction and use of the NV1020-like virus OncSyn to treat human breast tumors implanted in nude mice. The syncytial mutation gKsyn1 (Ala-to-Val at position 40) was introduced into the OncSyn...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.